Key statistics
On Friday, Novavax Inc (NVVX.A:GER) closed at 8.11, 25.38% above the 52 week low of 6.47 set on Nov 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.65 |
---|---|
High | 8.11 |
Low | 7.63 |
Bid | 8.10 |
Offer | 8.17 |
Previous close | 7.77 |
Average volume | 11.02k |
---|---|
Shares outstanding | 160.09m |
Free float | 153.08m |
P/E (TTM) | -- |
Market cap | 1.29bn USD |
EPS (TTM) | -2.26 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 16:35 GMT.
More ▼
Press releases
- Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
- Novavax to Participate in Jefferies London Healthcare Conference
- Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
- U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
- Åsa Manelius Named Managing Director of Novavax AB Site
- Åsa Manelius utnämnd till verkställande direktör för Novavax AB:s anläggning
- Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
- Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development
More ▼